CYTOKINETICS INC (CYTK) Stock Fundamental Analysis

NASDAQ:CYTK • US23282W6057

68.26 USD
+0.32 (+0.47%)
At close: Feb 23, 2026
68.26 USD
0 (0%)
After Hours: 2/23/2026, 4:13:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall CYTK gets a fundamental rating of 2 out of 10. We evaluated CYTK against 521 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTK have multiple concerns. CYTK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CYTK has reported negative net income.
  • In the past year CYTK has reported a negative cash flow from operations.
  • In the past 5 years CYTK always reported negative net income.
  • In the past 5 years CYTK reported 4 times negative operating cash flow.
CYTK Yearly Net Income VS EBIT VS OCF VS FCFCYTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

  • CYTK has a Return On Assets (-52.34%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -52.34%
ROE N/A
ROIC N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTK Yearly ROA, ROE, ROICCYTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CYTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTK Yearly Profit, Operating, Gross MarginsCYTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CYTK has more shares outstanding
  • CYTK has more shares outstanding than it did 5 years ago.
  • CYTK has a better debt/assets ratio than last year.
CYTK Yearly Shares OutstandingCYTK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CYTK Yearly Total Debt VS Total AssetsCYTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • Based on the Altman-Z score of -1.23, we must say that CYTK is in the distress zone and has some risk of bankruptcy.
  • CYTK has a Altman-Z score (-1.23) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.23
ROIC/WACCN/A
WACC8.33%
CYTK Yearly LT Debt VS Equity VS FCFCYTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • A Current Ratio of 6.88 indicates that CYTK has no problem at all paying its short term obligations.
  • CYTK's Current ratio of 6.88 is fine compared to the rest of the industry. CYTK outperforms 69.10% of its industry peers.
  • A Quick Ratio of 6.88 indicates that CYTK has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 6.88, CYTK is doing good in the industry, outperforming 69.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.88
Quick Ratio 6.88
CYTK Yearly Current Assets VS Current LiabilitesCYTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for CYTK have decreased strongly by -17.47% in the last year.
  • The Revenue has grown by 2609.26% in the past year. This is a very strong growth!
  • The Revenue has been decreasing by -7.24% on average over the past years.
EPS 1Y (TTM)-17.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.5%
Revenue 1Y (TTM)2609.26%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%318.14%

3.2 Future

  • Based on estimates for the next years, CYTK will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.83% on average per year.
  • CYTK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 236.19% yearly.
EPS Next Y-23.25%
EPS Next 2Y-8.38%
EPS Next 3Y4.73%
EPS Next 5Y18.83%
Revenue Next Year2381.58%
Revenue Next 2Y510.42%
Revenue Next 3Y387.73%
Revenue Next 5Y236.19%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CYTK Yearly Revenue VS EstimatesCYTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
CYTK Yearly EPS VS EstimatesCYTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CYTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTK Price Earnings VS Forward Price EarningsCYTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTK Per share dataCYTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.38%
EPS Next 3Y4.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CYTK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYTOKINETICS INC

NASDAQ:CYTK (2/23/2026, 4:13:43 PM)

After market: 68.26 0 (0%)

68.26

+0.32 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-24
Inst Owners117.53%
Inst Owner Change-12.02%
Ins Owners0.52%
Ins Owner Change1.14%
Market Cap8.35B
Revenue(TTM)87.21M
Net Income(TTM)-751.92M
Analysts80.77
Price Target91.56 (34.13%)
Short Float %11.09%
Short Ratio6.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.98%
Min EPS beat(2)-58.24%
Max EPS beat(2)20.28%
EPS beat(4)2
Avg EPS beat(4)-10.04%
Min EPS beat(4)-58.24%
Max EPS beat(4)20.28%
EPS beat(8)2
Avg EPS beat(8)-15.27%
EPS beat(12)2
Avg EPS beat(12)-20.48%
EPS beat(16)4
Avg EPS beat(16)-8.95%
Revenue beat(2)1
Avg Revenue beat(2)1299.97%
Min Revenue beat(2)-46.62%
Max Revenue beat(2)2646.57%
Revenue beat(4)3
Avg Revenue beat(4)870.43%
Min Revenue beat(4)-46.62%
Max Revenue beat(4)2646.57%
Revenue beat(8)3
Avg Revenue beat(8)406.55%
Revenue beat(12)4
Avg Revenue beat(12)259.37%
Revenue beat(16)6
Avg Revenue beat(16)381.31%
PT rev (1m)2.39%
PT rev (3m)16.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.23%
EPS NY rev (1m)0.59%
EPS NY rev (3m)-13.09%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)-34.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 95.69
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.32
EYN/A
EPS(NY)-6.18
Fwd EYN/A
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-3.54
OCFYN/A
SpS0.71
BVpS-4.26
TBVpS-4.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 212.08%
Cap/Sales 23.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.88
Quick Ratio 6.88
Altman-Z -1.23
F-Score3
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)82.69%
Cap/Depr(5y)599.06%
Cap/Sales(3y)17.31%
Cap/Sales(5y)28.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.5%
EPS Next Y-23.25%
EPS Next 2Y-8.38%
EPS Next 3Y4.73%
EPS Next 5Y18.83%
Revenue 1Y (TTM)2609.26%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%318.14%
Revenue Next Year2381.58%
Revenue Next 2Y510.42%
Revenue Next 3Y387.73%
Revenue Next 5Y236.19%
EBIT growth 1Y-9.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.43%
EBIT Next 3Y4.06%
EBIT Next 5Y24.98%
FCF growth 1Y-2.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.17%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOKINETICS INC / CYTK FAQ

What is the fundamental rating for CYTK stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYTK.


What is the valuation status for CYTK stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOKINETICS INC (CYTK). This can be considered as Overvalued.


Can you provide the profitability details for CYTOKINETICS INC?

CYTOKINETICS INC (CYTK) has a profitability rating of 0 / 10.


What is the expected EPS growth for CYTOKINETICS INC (CYTK) stock?

The Earnings per Share (EPS) of CYTOKINETICS INC (CYTK) is expected to decline by -23.25% in the next year.